Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

Robert Perrillo, Eugene Schiff, Eric Yoshida, Ann Statler, Kenneth Hirsch, Teresa Wright, Klaus Gutfreund, Patrick Lamy, Alison Murray

Research output: Contribution to journalArticle

453 Scopus citations

Abstract

Lamivudine has been shown to be an effective therapy for chronic hepatitis B, but resistance to this nucleoside agent is common after prolonged use. Five patients with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 9 to 19 months of treatment. In 4 patients this occurred after liver transplantation and the remaining individual had stable cirrhosis. In each case, resistance was confirmed to be caused by one or more mutations in the HBV-DNA polymerase gene and was associated with active underlying liver disease. The patients were treated with adefovir dipivoxil in a dose of 5 to 30 mg daily. Two to 4 log10 reductions in HBV-DNA levels were observed in 4 cases, and the fifth patient became negative by quantitative polymerase chain reaction (PCR) after retransplantation in conjunction with hepatitis B immunoglobulin (HBIg). Virologic improvement was associated with stable or declining serum alanine transaminase levels in 4 patients. HBV-DNA suppression has been sustained during a mean treatment period of 13 months (range 11 to 15 months), including 1 patient in whom lamivudine has been discontinued. Mild changes in renal function were observed during treatment in most cases but did not require early discontinuation of the drug. This study provides evidence that adefovir dipivoxil can be an effective treatment for lamivudine-resistant HBV mutants as well as wild-type HBV.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalHepatology
Volume32
Issue number1
DOIs
StatePublished - Jul 2000

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants'. Together they form a unique fingerprint.

  • Cite this

    Perrillo, R., Schiff, E., Yoshida, E., Statler, A., Hirsch, K., Wright, T., Gutfreund, K., Lamy, P., & Murray, A. (2000). Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 32(1), 129-134. https://doi.org/10.1053/jhep.2000.8626